Psychedelic Treatments Are Coming to Independent Practices
A federal push to expand mental health access, a landmark industry partnership, and a wave of clinic inquiries.
The window to get ahead of this is now.
Osmind has partnered with Compass Pathways to help independent clinics build the operational foundation to deliver novel psychedelic treatments.
Let's start with what you can do today.
Be the First to Know, and First to be Ready
We'll share the readiness checklist, partnership updates, and relevant resources as they're available.
Why Now?
The Policy Shift
A federal executive order signed in April 2026 directed the FDA to fast-track psychedelic compounds and allocated $50 million to accelerate research.
For independent psychiatry practices, the window to prepare is now.
Our Response
Osmind has partnered with Compass Pathways, the company developing COMP360 (synthetic psilocybin), to map what independent clinics need operationally to deliver these treatments.
You're Not Alone
We’re hearing from practices across the country asking the same question:
"How do we prepare?"
We're here to help.
Coming Soon: The Independent Clinic Readiness Checklist
Developed with Compass Pathways, see where your practice stands and what gaps to close before psychedelic treatments arrive. Sign up in the form above to be notified when it’s ready.
